This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?
by Debanjana Dey
bioAffinity's CyPath Lung sales momentum is gaining traction, but wider losses, funding needs and regulatory risks keep pressure on the stock.
BIAFNegative Net Change ADMANegative Net Change ALXONegative Net Change
biotechnology biotechs medical medical-devices
Stocks Look Shaky, But This Sector is Booming (Biotech)
by Ethan Feller
Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.
LLYNegative Net Change ILMNNegative Net Change EXELNegative Net Change XLVPositive Net Change PTCTNegative Net Change XBINegative Net Change FTREPositive Net Change
biotechs
PRTA Stock Rises Nearly 11% in Six Months: What's Driving It?
by Zacks Equity Research
Prothena shares climb as late-stage partnered programs advance, milestone payments strengthen finances and its neurodegenerative pipeline continues to expand.
PRTANegative Net Change RHHBYNegative Net Change BMYPositive Net Change NVONegative Net Change
biotechs
TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know
by Zacks Equity Research
Tvardi Therapeutics stock jumps this week as phase I data for TTI-109 highlight improved tolerability, target engagement and support plans for mid-stage development.
TVRDPositive Net Change NVAXNegative Net Change AMRNNegative Net Change LQDANegative Net Change
biotechnology biotechs medical pharmaceuticals
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
by Zacks Equity Research
Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism.
NTLANegative Net Change BEAMNegative Net Change CRSPNegative Net Change
biotechs
Buyout Buzz Around VKTX Is Back: What's Fueling the Speculation?
by Sundeep Ganoria
Viking Therapeutics' expanding obesity pipeline and upcoming VK2735 data reignite buyout speculation as investors weigh its growing strategic appeal.
VKTXNegative Net Change NVONegative Net Change LLYNegative Net Change
biotechs medical pharmaceuticals
AstraZeneca's Stock Drops on Wainua's Setback in ATTR-CM Study
by Zacks Equity Research
AZN shares tumble after Wainua missed the primary endpoint in a late-stage ATTR-CM study, raising questions about its expansion into a larger market.
AZNNegative Net Change ALNYNegative Net Change IONSNegative Net Change BBIONegative Net Change
biotechs medical pharmaceuticals
DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?
by Zacks Equity Research
Denali Therapeutics surges on Avlayah???s FDA approval, PRV sale and pipeline progress, but partnership changes and trial setbacks remain in focus.
DNLIPositive Net Change SNYPositive Net Change BIIBPositive Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Is ADMA Stock's 13.5% Monthly Gain a Sign of Recovery?
by Ekta Bagri
ADMA shares rebound 13.5% in a month after a steep decline, even as lowered 2026 guidance and IG market competition continue to weigh on sentiment.
ADMANegative Net Change GRFSNegative Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
BridgeBio Stock Taps Rare Disease Trends and New Diagnosis Growth
by Sundeep Ganoria
BBIO builds on Attruby's launch as rising rare disease diagnoses and late-stage pipeline candidates set up multiple potential U.S. launches.
BBIONegative Net Change PFEPositive Net Change BMRNPositive Net Change ASNDNegative Net Change
biotechs medical pharmaceuticals